ArticleNPJ vaccines2026
Prefusion-stabilized SARS-CoV-2 spike reshapes antigenic hierarchy and antibody targeting against conserved and occluded epitopes.
Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cavity-Filling Mutations as a Strategy to Stabilize Prefusion Viral Fusion Proteins for Vaccine Design.Computational and structural biotechnology journal · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike contains multiple classes of antibody epitopes that are associated with diverse neutralizing activities. Although both natural infection and vaccination robustly elicit RBD-reactive and neutralizing antibodies, the spike antigenic structures presented to the immune system may differ, leading to qualitative differences in the antibody responses. Using large and well-controlled cohorts, we show that the neutralizing potency index (NPI), calculated as the ratio of neutralizing titer to RBD IgG titer, is approximately fivefold lower in vaccine recipients than in convalescent individuals, independent of disease severity, comorbidities, or demographic factors. This reduction in NPI is associated with enhanced antibody targeting to non-neutralizing, yet conserved and structurally occluded RBD epitope. Molecular dynamics (MD) simulations together with the binding assay demonstrate that the occluded epitope is allosterically exposed by stabilizing mutations introduced into the vaccine spike antigen, a process mediated by a highly extended RBD-up conformation. Collectively, our findings demonstrate that RBD conformational modulation by stabilizing mutations shapes vaccine antigenicity and likely alters the epitope landscape of antibody responses.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.